Literature DB >> 17220672

[Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].

Yoshiaki Rai1, Yoshiaki Sagara, Yasuaki Sagara, Tetsuya Takahama, Yoshito Matsuyama, Mitsutake Ando, Yoshiatsu Sagara, Yasuyo Ooi, Kenichi Inoue, Masafumi Kurosumi.   

Abstract

A 53-year-old woman had a 105x100 mm tumor on her right breast with a 55x36 mm-sized bleeding ulcer of the skin and ipsilateral axillary and cervical lymph nodes swelling (T4bN3cM1, Stage IV). Core needle biopsy and immunohistochemistry of breast tumor showed invasive ductal carcinoma with negative hormone receptor (ER-, PgR-) and overexpression of HER 2 (Hercep Test score 3+). She was treated with weekly trastuzumab (initially 4 mg/kg followed by 2 mg/kg every week), and a combination of tri-weekly paclitaxel (175 mg/m(2), 6 courses). After 3 courses of administration, the breast tumor subsided, the ulcer became flat, and axillary and cervical nodes completely disappeared. Clinical CR was obtained after 6 courses of treatment, and mastectomy with axillary clearance was then performed. Histopathology of the breast and lymph nodes showed complete disappearance of cancer cells (pCR, Grade 3+3 (d) +3 (n)). The combination of trastuzumab and paclitaxel is a promising regimen for HER 2 positive advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220672

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.

Authors:  Hideo Shigematsu; Yoshiaki Nakamura; Kimihiro Tanaka; Satoko Shiotani; Chinami Koga; Hidetoshi Kawaguchi; Sumiko Nishimura; Kenichi Taguchi; Kenichi Nishiyama; Shinji Ohno
Journal:  Int J Clin Oncol       Date:  2010-05-15       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.